dupilumab
dupilumab: 69 clinical trials tracked.
dupilumab evidence translation
What we can confirm
69 tracked trials
What it means
What to watch
Prepared research question
What is verified about dupilumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Clinical Trial Registry Records (69)showing 10 most recent
An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous Pemphigoid
An Open Label, Expanded Access Program of Dupilumab in Adults With Severe IgE-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab
Master Protocol for A Phase 1b/2 Study of Neoadjuvant Immunotherapy in Microsatellite Stable (MSS) Colorectal Cancer (CRC) Subjects With Resectable Liver Metastases
Primary endpoint: Number of dose limiting toxicities (DLTs)
A Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy of Dupilumab Added on to Standard of Care (SOC) Treatment vs SOC Treatment Following Hospitalization for a COPD Exacerbation
Primary endpoint: Time to first all-cause event
Phase 1, Single Center, Open-label, Randomized, Parallel-group Study to Evaluate Pharmacokinetics and Tolerability of a Single Subcutaneous Dose of Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
Primary endpoint: Pharmacokinetic (PK) parameter in serum: Cmax of dupilumab
A Prospective Observational Study of Patients Receiving Dupilumab for Chronic Spontaneous Urticaria
Primary endpoint: Summary of Sociodemographic Characteristics
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
Primary endpoint: Proportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof-of-Concept Study to Evaluate the Efficacy and Safety of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Primary endpoint: Percentage change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16
A Multinational, Investigator-initiated, Parallel Group, Randomised, Double-blind, Placebo-controlled Phase 3b Superiority Trial Assessing the Effect of Dupilumab on Inducing Clinical Remission Outcomes in At-risk Type-2 Inflammatory Asthma (HOTHOT)
Primary endpoint: Win ratio based on remission criteria
Singapore-Malaysian Renal Trials - Nephrotic Syndrome (SMART-NS): Dupilumab Maintenance Therapy for Steroid-dependent and Frequently Relapsing Nephrotic Syndrome
Primary endpoint: Time to relapse